.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I believe that PARD could possibly be a 50% gainer by end of 1H2010.
As you said, potentially price moving forward-looking events coming up as well:
http://finance.yahoo.com/news/Poniard-Pharmaceuticals-prnews-1983655420.html?x=0&.v=1
If the talks w/ the FDA go well, this could definitely go back into the $3s/$4s, imo.
GL.
Good day today. Looking forward to what GNVC and DDSS have in store for tomorrow.
GLTA.
I honestly believe that it could slide back down to mid-low .60s again soon. However, if there is some trial/partner news released, it could go up to $1 or $2, imo.
GLTA.
Holding up fairly well after the move yesterday. Back in the .65s...
GLTA.
Nice move... Back up in the 2.13s...
GLTA.
DDSS could possibly go up to $3-$4 pre-approval... According to some posts I've read on the yahoo board, they're currently in partnership talks, and a parter could come before approval (Feb. 11) in order to be as prepared as possible for product launch, imo.
Holding low .70s as well... Nice
GL.
Boardmarked... Put my order in tonight.
GLTA.
COME ON $1!!!
GLTA.
GNVC news out. Partnership w/ Novartis for pre-clinical hearing loss drug.
GLTA.
New article out... AF has same price target for ANX that he has for CTIC - .20-.30 per share... LOL! I wonder if he'll say the same if/when ANX gets to $1?
GL.
INVO Bioscience Announces the Signing of Distribution Company BioGenini Medical EOOD
BEVERLY, MA--(Marketwire - 01/19/10) - INVO Bioscience, Inc. (OTC.BB:IVOB - News), a medical device company focused on treatment options for patients diagnosed with infertility, announced the signing of Bulgarian distribution company BioGenini Medical EOOD. BioGenini Medical is a medical device distribution and research company that is now looking into new concepts that will allow for affordable infertility treatment. INVO Bioscience CEO Katie Karloff stated, "The shortage of a cost effective treatment has left a lot of couples simply out of reach. I believe that INVO Bioscience partnered with BioGenini can bring an affordable infertility treatment to couples in Bulgaria."
INVOcell product registration was started by BioGenini during the middle of December 2009 and should be completed within the coming months. Bulgaria currently has a dangerously low replacement rate of 1.2 children per couple. A single IVF cycle in Bulgaria is around $3,800 while an average yearly salary in Bulgaria is estimated at $4,602. The government and insurance companies offer no support for IVF. BioGenini will look to expand the INVO procedure first into Bulgaria and if successful may expand INVO into other parts of Eastern Europe.
About the INVO Procedure
The INVOcell and INVO Procedure combine a natural or mild (mild medication) stimulation infertility treatment cycle, using lower amounts of fertility hormones than used in traditional IVF (in vitro fertilization), with intra-vaginal incubation (IVC) of sperm and eggs. Following standard egg retrieval, the woman's eggs (oocytes) are combined with sperm in the INVOcell, a small device, which is then sealed and placed in the woman's vaginal cavity to incubate for three days. When the INVOcell is removed, the anticipated one to two developing embryos are transferred directly into the woman's uterine cavity, where implantation and continued pregnancy can take place.
The company has received European CE Mark approval for the INVOcell in 2008 and launched the product in select countries outside the U.S. The company is also pursuing U.S. Food and Drug Administration 510(k) clearance for the INVOcell.
About INVO Bioscience
INVO Bioscience (IVOB) is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit www.invobioscience.com.
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Good Morning All!
I agree 100%... ANX is a definite winner, imo.
BTW, Happy Birthday!
iBox updated... If anything needs added lmk.
GLTA.
Orion Party Bash MLK Day Contest Pick - APPA
Orion Party Bash MLK Day Contest Pick: MNKD
Thanks for the link!
Have a great 3-day weekend all!
lol. I agree. AF bashed CTIC @ .20-.30 as well, later on it went up to $2. IMO, ANX will do the same thing.
GL.
Repros Approved for Trading on Nasdaq Capital Market
Repros Therapeutics Inc. (NasdaqCM:RPRX) today announced that Nasdaq has granted the Company until May 5, 2010 to meet the continued listing requirements of the Nasdaq Capital Market. Repros began trading on the Nasdaq Capital Market on January 14, 2010. Nasdaq noted the progress made by Repros in resolving creditor debt, as well as the progress the Company has made in executing the plan to regain compliance that was presented to the Appeals Committee in December if the Company was allowed to move to the Nasdaq Capital Markets as part of its decision to allow the Company the additional time
Joseph S. Podolski, President and CEO of Repros, noted, “We are thankful that Nasdaq has approved our application to move to the Nasdaq Capital Market and granted us the additional time to gain compliance with its listing requirements. The ability to remain a Nasdaq listed Company allows us the greatest flexibility as we consider our financing options going forward. We believe that we will be able to gain compliance with the listing requirements by the May 5, 2010 date.” In accordance with the decision of the Nasdaq Hearings Panel, Repros has to meet all of the continued listing requirements of the Nasdaq Capital Market by May 5, 2010, or its securities will, in all likelihood, be delisted from The Nasdaq Stock Market promptly following such date. A Company that has its Primary Equity Security listed on the Capital Market must continue to meet all of the requirements set forth in Rule 5550(a) and at least one of the Standards set forth in Rule 5550(b)
(a) Continued Listing Requirements for Primary Equity Securities: (1) At least two registered and active Market Makers, one of which may be a Market Maker entering a stabilizing bid; (2) Minimum bid price of at least $1 per share; (3) At least 300 Public Holders; (4) At least 500,000 Publicly Held Shares; and (5) Market Value of Publicly Held Shares of at least $1 million
(b) Continued Listing Standards for Primary Equity Securities: (1) Equity Standard: Stockholders' equity of at least $2.5 million; or (2) Market Value of Listed Securities Standard: Market Value of Listed Securities of at least $35 million; or (3) Net Income Standard: Net income from continuing operations of $500,000 in the most recently completed fiscal year or in two of the three most recently completed fiscal years
About Repros Therapeutics Inc. Repros Therapeutics focuses on the development of oral small molecule drugs for major unmet medical needs that treat male and female reproductive disorders
Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including Repros' ability to maintain its listing on the NASDAQ Capital Market, raise needed additional capital on a timely basis in order for it to continue its operations, have success in the clinical development of its technologies, successfully defend itself against the class action complaints, whether clinical trials of Proellex® may be resumed, whether any safe and effective dose for Proellex can be determined, whether a clear clinical path for Androxal® can be determined and such other risks which are identified in the Company's most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from Repros Therapeutics or at www.sec.gov. Repros disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise
For more information, please visit the Company's website at http://www.reprosrx.com
ANDS should move up in the coming weeks. Second cohort of phase 2 trial should be out this year. Lots of potential, imo.
GLTA.
Here's a look at their pipeline, looks like some fairly promising drugs: http://www.transitiontherapeutics.com/technology/index.php
GLTA.
Insider information: http://www.mffais.com/tthi
Inching up a bit before close... 0.7698 ask.
GLTA.
Too much red in the market today for it to have much action. Tuesday will be a whole different story, imo.
GLTA.
I'm really surprised it dropped this much after that conference. Hopefully it'll bounce up to the .40s again next week.
GL.
$1.91
Nice call!
Yeah. IMO, APPA will be at least at the mid-3s by the PDUFA date, maybe more.
GL.
Good day today.. BNVI news, HEB broke thru .70s, NEXM held steady, and ANX provided a good entry point for those looking to get in.
GLTA.
We closed @ .58 after hours.
Take this w/ a grain of salt, but stockconsultant.com says possible breakout over .61 w/ .82 target: http://www.nasdaq.com/asp/stock_consultant.asp?symbol=NEXM&selected=NEXM
GLTA.
NEXM is almost 100% over where it was last Thursday. One more positive PR like the one on Tuesday and we're over $1, imo.
GLTA.
Thanks for the tip!
GL.
Re-entered GNVC today... Going to $3 by mid-Feb, imo.
GLTA.
http://www.nasdaq.com/aspxcontent/ExtendedTradingTrades.aspx?selected=BNVI&mkttype=after
Great action on BNVI after-hours!
GLTA.
IMO, if they decide to raise money, they'll wait until after they've reached $1 sh/price and after they have everything straightened out w/ NASDAQ listing.
jmo.
GL.
.65 break coming soon, imo...
GLLs
We break thru .70 and we could have a squeeze, imo.
GLTY.